TBG Diagnostics (OTCMKTS:TDLAF – Get Rating) and Exactus (OTCMKTS:EXDI – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Volatility & Risk
TBG Diagnostics has a beta of -12.38, suggesting that its share price is 1,338% less volatile than the S&P 500. Comparatively, Exactus has a beta of 4.21, suggesting that its share price is 321% more volatile than the S&P 500.
0.1% of Exactus shares are owned by institutional investors. 3.6% of TBG Diagnostics shares are owned by insiders. Comparatively, 65.0% of Exactus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares TBG Diagnostics and Exactus’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TBG Diagnostics||$2.33 million||1.02||$530,000.00||N/A||N/A|
|Exactus||$2.07 million||159.13||-$9.46 million||N/A||N/A|
TBG Diagnostics has higher revenue and earnings than Exactus.
This is a summary of recent ratings for TBG Diagnostics and Exactus, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares TBG Diagnostics and Exactus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About TBG Diagnostics (Get Rating)
TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.
About Exactus (Get Rating)
Exactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.
Receive News & Ratings for TBG Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TBG Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.